Press release

Sprint Bioscience congratulates Yoshinori Ohsumi on the Nobel prize

At Sprint Bioscience we are very happy that a field of research that we have actively pursued for more than 5 years is now being rewarded the Nobel prize in medicine. Sprint Bioscience is a Swedish company that since the start has been running a project for autophagy inhibition for cancer treatment. The project is…

Read more →

Press release

Sprint Bioscience enters into collaboration with US Drug Development Company on tumor metabolism program

Sprint Bioscience AB (publ) (Sprint Bioscience) and a US drug development company (Company) have entered into a collaboration and license agreement for the research, development, and commercialization of Sprint Bioscience’s PIP4K2a program targeting tumor metabolism. Under the agreement, Sprint Bioscience licenses a PIP4k2a inhibitor program targeting tumor metabolism to the Company. Subsequently, the Company will…

Read more →

Press release

Sprint Bioscience starts a diabetes program

Sprint Bioscience has signed a collaboration agreement with the Lundberg Laboratory for Diabetes Research at Gothenburg University in which Sprint Bioscience will develop drug candidates against a new target protein that is central to the development of type 2 diabetes. Sprint Bioscience has in fact already identified series of substances and a chemistry program is in place. The molecules will be evaluated in disease models developed for diabetes research at the Lundberg Laboratory. The aim is to initiate out-licensing of the project in 2016, when the identity of the target molecules will also be made known.

Press release

Sprint Bioscience starts a diabetes program

Sprint Bioscience has signed a collaboration agreement with the Lundberg Laboratory for Diabetes Research at Gothenburg University in which Sprint Bioscience will develop drug candidates against a new target protein that is central to the development of type 2 diabetes. Sprint Bioscience has in fact already identified series of substances and a chemistry program is in place. The molecules will be evaluated in disease models developed for diabetes research at the Lundberg Laboratory. The aim is to initiate out-licensing of the project in 2016, when the identity of the target molecules will also be made known.

Press release

Sprint Bioscience enters into collaboration with Bayer HealthCare on tumor metabolism program

"We are very happy to have entered into this agreement for one of our tumor metabolism projects. We are convinced that Bayer is a perfect partner to further develop this program. "Anders Åberg, CEO, Sprint Bioscience "We are looking forward to expanding our portfolio in this area through the agreement with Sprint Bioscience. This early…

Read more →

Press release

Sprint Bioscience enters into collaboration with Bayer HealthCare on tumor metabolism program

"We are very happy to have entered into this agreement for one of our tumor metabolism projects. We are convinced that Bayer is a perfect partner to further develop this program. "Anders Åberg, CEO, Sprint Bioscience "We are looking forward to expanding our portfolio in this area through the agreement with Sprint Bioscience. This early…

Read more →

Press release

Promising results for the treatment of intractable breast cancer

Sprint Bioscience has successfully demonstrated that the company’s Vps34 inhibitors have good efficacy in an animal model of triple-negative breast cancer (TNBC), a severe form of breast cancer that can easily metastasize. TNBC affects around 90,000 women each year in the EU and the US. On 20 October, Sprint Bioscience announced that the company’s preliminary…

Read more →

Press release

PRESS RELEASE

“Forska&Väx” grants to Sprint Bioscience for the development of drugs to treat intractable cancer. Through its “Forska&Väx” program VINNOVA is funding the Stockholm-based biotechnology company, Sprint Bioscience with 1 900 000 SEK for new treatment of tumors that have become resistant to cancer drugs. Stockholm, 2013-11-27 – Sprint Bioscience has Nov. 18 been awarded funding from VINNOVA’s…

Read more →